Safety pharmacology methods: Anticipating the transition from long QT (LQTS) to short QT syndromes (SQTS)?

Journal of Pharmacological and Toxicological Methods

Volumn 56, Issue 2, 2007, Pages 87-90

  Pugsley, Michael K ^a   Curtis, Michael J ^b  

^a Johnson and Johnson PRD ^*  (United States)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BIOLOGICAL MARKER; CHLORPROMAZINE; CLONIDINE; DIAZEPAM; PENTETRAZOLE; QUINIDINE;

BLOOD FLOW; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE POTENTIAL; HEART OUTPUT; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMIC PARAMETERS; HUMAN; LONG QT SYNDROME; NONHUMAN; PURKINJE FIBER; RISK ASSESSMENT; SHORT QT SYNDROME;

ANIMALS; CARDIAC ELECTROPHYSIOLOGY; DRUG EVALUATION, PRECLINICAL; HUMANS; LONG QT SYNDROME; MODELS, ANIMAL; PHARMACOLOGY; REPRODUCIBILITY OF RESULTS;

EID: 34548550667     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2007.05.003     Document Type: Editorial

References (26)

1. Antzelevitch C., and Francis J. Congenital short QT syndrome. Indian Pacing Electrophysiol J 4 (2004) 46-49
2. Antzelevitch C., Pollevick G.D., Cordeiro J.M., Casis O., Sanguinetti M.C., Aizawa Y., et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 115 (2007) 442-449
3. Authier S., Tanguay J.-F., Gauvin D., Di Fruscia R., Fournier S., Chaurand F., and Troncy E. A cardiovascular monitoring system in conscious cynomolgus monkeys for regulatory safety pharmacology: Part 1: Non-pharmacological validation. Journal of Pharmacological & Toxicological Methods 56 (2007) 115-121 10.1016/j.vascn.2007.03.010
4. Authier S., Tanguay J.-F., Gauvin D., Di Fruscia R., and Troncy E. A cardiovascular monitoring system in conscious cynomolgus monkeys for regulatory safety pharmacology: Part 2: Pharmacological validation. Journal of Pharmacological & Toxicological Methods 56 (2007) 122-130 10.1016/j.vascn.2007.03.011
5. Bass A., Valentin J.-P., Fossa A.A., and Volders P.G.A. Points to consider emerging from a mini-workshop on cardiac safety: Assessing torsades de pointes liability. Journal of Pharmacological & Toxicological Methods 56 (2007) 91-94 10.1016/j.vascn.2007.05.001
6. Bjerregaard P., Jahangir A., and Gussak I. Targeted therapy for short QT syndrome. Expert Opinion Therapeutic Targets 10 (2006) 393-400
7. Borchert B., Lawrenz T., and Stellbrink C. Long and short QT syndrome. Herzschrittmachertherapie & Elektrophysiologie 17 (2006) 205-210
8. Chiang A.Y., Bass A.S., Cooper M.M., Engwall M.J., Menton R.G., and Thomas K. ILSI-HESI cardiovascular safety subcommittee dataset: An analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc). Journal of Pharmacological & Toxicological Methods 56 (2007) 95-102 10.1016/j.vascn.2007.04.002
9. Committee for Medicinal Products for Human Use (CHMP). EMEA/SWP/36191. Guideline on the Non-Clinical investigation of the dependence potential of medicinal products (2006)
10. Ducroq J., Printemps R., Guilbot S., Gardette J., Salvetat C., and Le Grand M. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies. Journal of Pharmacological & Toxicological Methods 56 (2007) 159-170 10.1016/j.vascn.2007.03.009
11. Dürmüller N., Guillaume P., Lacroix P., Porsolt R.D., and Moser P. The use of the dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant risk. Journal of Pharmacological & Toxicological Methods 56 (2007) 234-238 10.1016/j.vascn.2007.03.006
12. Easter A., Sharp T.H., Valentin J.-P., and Pollard C.E. Pharmacological validation of a semi-automated in vitro hippocampal brain slice assay for assessment of seizure liability. Journal of Pharmacological & Toxicological Methods 56 (2007) 223-233 10.1016/j.vascn.2007.04.008
13. Federal Register. ICHS7A: Safety pharmacology studies for human pharmaceuticals. Federal Register 66 (2001) 36791-36792
14. Federal Register. ICHS7B: Safety pharmacology studies for assessing the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals. Federal Register 67 (2002) 40950-40951
15. Gaita F., Giustetto C., Bianchi F., Schimpf R., Haissaguerre M., Calò L., et al. Short QT syndrome: Pharmacological treatment. Journal of the American College of Cardiology 43 (2004) 1494-1499
16. Himmel H.M. Suitability of commonly used excipients for electrophysiological in-vitro safety assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential. Journal of Pharmacological & Toxicological Methods 56 (2007) 145-158 10.1016/j.vascn.2007.04.004
17. Hondeghem. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. Journal of Cardiovascular Electrophysiology 17 (2006) 337-340
18. Lawrence C.L., Pollard C.E., Hammond T.G., and Valentin J.P. Nonclinical proarrhythmia models: predicting Torsades de Pointes,. Journal of Pharmacological & Toxicological Methods 52 (2005) 46-59
19. Lightbown I.D., Johnson M., Davis A., Leaney J., and Leishman D.J. Towards automation of a valuable preclinical cardiac safety pharmacology assay: Evaluation of the effects of cardiac ion channel blockers on cardiac repolarisation in vitro. Journal of Pharmacological & Toxicological Methods 56 (2007) 194-202 10.1016/j.vascn.2007.03.008
20. Markert M., Klumpp A., Trautmann T., Mayer K., Stubhan M., and Guth B. The value added by measuring myocardial contractility 'in vivo' in safety pharmacological profiling of drug candidates. Journal of Pharmacological & Toxicological Methods 56 (2007) 203-211 10.1016/j.vascn.2007.03.004
21. Moscardo E., Maurin A., Dorigatti R., Champeroux P., and Richard S. An optimized methodology for the neurobehavioural assessment in rodents. Journal of Pharmacological & Toxicological Methods 56 (2007) 239-255 10.1016/j.vascn.2007.03.007
22. Shah R.R., and Hondeghem L.M. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2 (2005) 758-772
23. Taylor G.L., Patel B., and Sullivan A.T. Evaluation of blood flow parameters in addition to blood pressure and electrocardiogram in the conscious telemetered beagle dog. Journal of Pharmacological & Toxicological Methods 56 (2007) 212-217 10.1016/j.vascn.2007.04.003
24. Terrar D.A., Wilson C.M., Graham S.G., Bryant S.M., and Heath B.M. Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. Journal of Pharmacological & Toxicological Methods 56 (2007) 171-185 10.1016/j.vascn.2007.04.005
25. Tontodonati M., Fasdelli N., Moscardo E., Giarola A., and Dorigatti R. A canine model used to simultaneously assess potential neurobehavioural and cardiovascular effects of candidate drugs. Journal of Pharmacological & Toxicological Methods 56 (2007) 265-275 10.1016/j.vascn.2007.03.005
26. Valentin J.P., Hoffmann P., De Clerck F., Hammond T.G., and Hondeghem L. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. Journal of Pharmacological & Toxicological Methods 49 (2004) 171-181